Treatment with afobazole at delayed time points following ischemic stroke improves long-term functional and histological outcomes

Neurobiology of Disease

Volumn 62, Issue , 2014, Pages 354-364

  Katnik, C ^a   Garcia, A ^a   Behensky, A A ^a   Yasny, I E ^b   Shuster, A M ^b   Seredenin, S B ^c   Petrov, A V ^b   Seifu, S ^a   McAleer, J ^a   Willing, A ^a   Cuevas, J ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b IBC Generium   (Russian Federation)

^c INSTITUTE OF PHARMACOLOGY   (Russian Federation)

Author keywords

Afobazole; Behavior; Ischemic stroke; Middle cerebral artery occlusion; Neuroprotection; Oligodendroglia; Sigma receptor

Indexed keywords

AFOBAZOLE; ANXIOLYTIC AGENT; BD 1063; RECEPTOR BLOCKING AGENT; SM 21; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; BRAIN TISSUE; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; GRIP STRENGTH; IN VIVO STUDY; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NONHUMAN; PRIORITY JOURNAL; RAT; SURVIVAL; TREATMENT OUTCOME; WHITE MATTER;

AFOBAZOLE; BEHAVIOR; ISCHEMIC STROKE; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROPROTECTION; OLIGODENDROGLIA; SIGMA RECEPTOR;

ANIMALS; BENZIMIDAZOLES; BRAIN ISCHEMIA; HAND STRENGTH; INFARCTION, MIDDLE CEREBRAL ARTERY; MALE; MORPHOLINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, SIGMA; STROKE; TREATMENT OUTCOME;

EID: 84887379919     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2013.10.011     Document Type: Article

References (35)

1. Ajmo C.T., Vernon D.O., Collier L., Pennypacker K.R., Cuevas J. Sigma receptor activation reduces infarct size at 24hours after permanent middle cerebral artery occlusion in rats. Curr. Neurovasc. Res. 2006, 3:89-98.
2. Allen N.B., Kaltenbach L., Goldstein L.B., Olson D.M., Smith E.E., Peterson E.D., Schwamm L., Lichtman J.H. Regional variation in recommended treatments for ischemic stroke and TIA: Get with the Guidelines-Stroke 2003-2010. Stroke 2012, 43:1858-1864.
3. Baykova V.S., Kadnikov I.A., Voronin M.V., Ganshina T.S., Gnezdilova A.V., Gorbunov A.A., Mirzoyan P.C., Seredenin S.B. Effects of afobazole on the content of neurotransmitter amino acids in the striatum in global transient ischemia. Bull. Exp. Biol. Med. 2011, 151:593-596.
4. Behensky A.A., Yasny I.E., Shuster A.M., Seredenin S.B., Petrov A.V., Cuevas J. Afobazole activation of sigma-1 receptors modulates neuronal responses to amyloid-beta25-35. J. Pharmacol. Exp. Ther. 2013, 347:468-477.
5. Borlongan C.V., Hida H., Nishino H. Early assessment of motor dysfunctions aids in successful occlusion of the middle cerebral artery. Neuroreport 1998, 9:3615-3621.
6. Butler T.L., Kassed C.A., Sanberg P.R., Willing A.E., Pennypacker K.R. Neurodegeneration in the rat hippocampus and striatum after middle cerebral artery occlusion. Brain Res. 2002, 929:252-260.
7. Cuevas J., Behensky A., Deng W., Katnik C. Afobazole modulates neuronal response to ischemia and acidosis via activation of sigma-1 receptors. J. Pharmacol. Exp. Ther. 2011, 339:152-160.
8. Cuevas J., Rodriguez A., Behensky A., Katnik C. Afobazole modulates microglial function via activation of both sigma-1 and sigma-2 receptors. J. Pharmacol. Exp. Ther. 2011, 339:161-172.
9. Dewar D., Underhill S.M., Goldberg M.P. Oligodendrocytes and ischemic brain injury. J. Cereb. Blood Flow Metab. 2003, 23:263-274.
10. Dittmar M.S., Vatankhah B., Fehm N.P., Retzl G., Schuierer G., Bogdahn U., Schlachetzki F., Horn M. The role of ECA transection in the development of masticatory lesions in the MCAO filament model. Exp. Neurol. 2005, 195:372-378.
11. Erdo F., Berzsenyi P., Nemet L., Andrasi F. Talampanel improves the functional deficit after transient focal cerebral ischemia in rats. A 30-day follow up study. Brain Res. Bull. 2006, 68:269-276.
12. Galaeva I.P., Garibova T.L., Voronina T.A., Seredenin S.B. Neuroprotective effects of afobazol in experimental cerebral hemorrhage. Bull. Exp. Biol. Med. 2005, 140:535-537.
13. Ghelardini C., Galeotti N., Bartolini A. Pharmacological identification of SM-21, the novel sigma(2) antagonist. Pharmacol. Biochem. Behav. 2000, 67:659-662.
14. Kozhechkin S.N. Comparative electroencephalographic evaluation of anxiolytics afobazol and diazepam in MR and MNRA inbred rats with different anxiety levels. Eksp. Klin. Farmakol. 2003, 66:38-41.
15. Lees K.R., Bluhmki E., von Kummer R., Brott T.G., Toni D., Grotta J.C., Albers G.W., Kaste M., Marler J.R., Hamilton S.A., Tilley B.C., Davis S.M., Donnan G.A., Hacke W., Allen K., Mau J., Meier D., del Zoppo G., De Silva D.A., Butcher K.S., Parsons M.W., Barber P.A., Levi C., Bladin C., Byrnes G. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010, 375:1695-1703.
16. Leonardo C.C., Hall A.A., Collier L.A., Green S.M., Willing A.E., Pennypacker K.R. Administration of a sigma receptor agonist delays MCAO-induced neurodegeneration and white matter injury. Transl. Stroke Res. 2010, 1:135-145.
17. Leonards C.O., Ipsen N., Malzahn U., Fiebach J.B., Endres M., Ebinger M. White matter lesion severity in mild acute ischemic stroke patients and functional outcome after 1year. Stroke 2012, 43:3046-3051.
18. Li Z., Cui S., Zhang Z., Zhou R., Ge Y., Sokabe M., Chen L. DHEA-neuroprotection and -neurotoxicity after transient cerebral ischemia in rats. J. Cereb. Blood Flow Metab. 2009, 29:287-296.
19. Matsumoto R.R., Mack A.L. (+/-)-SM 21 attenuates the convulsive and locomotor stimulatory effects of cocaine in mice. Eur. J. Pharmacol. 2001, 417:R1-R2.
20. Matsumoto R.R., Bowen W.D., Tom M.A., Vo V.N., Truong D.D., De Costa B.R. Characterization of two novel sigma receptor ligands: antidystonic effects in rats suggest sigma receptor antagonism. Eur. J. Pharmacol. 1995, 280:301-310.
21. Matsumoto R.R., McCracken K.A., Friedman M.J., Pouw B., De Costa B.R., Bowen W.D. Conformationally restricted analogs of BD1008 and an antisense oligodeoxynucleotide targeting sigma1 receptors produce anti-cocaine effects in mice. Eur. J. Pharmacol. 2001, 419:163-174.
22. Matsumoto R.R., Pouw B., Mack A.L., Daniels A., Coop A. Effects of UMB24 and (+/-)-SM 21, putative sigma2-preferring antagonists, on behavioral toxic and stimulant effects of cocaine in mice. Pharmacol. Biochem. Behav. 2007, 86:86-91.
23. McCracken K.A., Bowen W.D., Matsumoto R.R. Novel sigma receptor ligands attenuate the locomotor stimulatory effects of cocaine. Eur. J. Pharmacol. 1999, 365:35-38.
24. Medvedev V.E., Trosnova A.P., Dobrovol'skii A.V. Psychopharmacotherapy of anxiety disorders in patients with cardio-vascular diseases: the use of aphobazole. Zh. Nevropatol. Psikhiatr. Im. S. S. Korsakova 2007, 107:25-29.
25. Meyer O.A., Tilson H.A., Byrd W.C., Riley M.T. A method for the routine assessment of fore- and hindlimb grip strength of rats and mice. Neurobehav. Toxicol. 1979, 1:233-236.
26. Modo M., Stroemer R.P., Tang E., Veizovic T., Sowniski P., Hodges H. Neurological sequelae and long-term behavioural assessment of rats with transient middle cerebral artery occlusion. J. Neurosci. Methods 2000, 104:99-109.
27. Ruscher K., Shamloo M., Rickhag M., Ladunga I., Soriano L., Gisselsson L., Toresson H., Ruslim-Litrus L., Oksenberg D., Urfer R., Johansson B.B., Nikolich K., Wieloch T. The sigma-1 receptor enhances brain plasticity and functional recovery after experimental stroke. Brain 2011, 134:732-746.
28. Ruscher K., Inacio A.R., Valind K., Rowshan Ravan A., Kuric E., Wieloch T. Effects of the sigma-1 receptor agonist 1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl)-piperazine dihydro-chloride on inflammation after stroke. PLoS One 2012, 7:e45118.
29. Ryan C.L., Doucette T.A., Gill D.A., Langdon K.D., Liu Y., Perry M.A., Tasker R.A. An improved post-operative care protocol allows detection of long-term functional deficits following MCAo surgery in rats. J. Neurosci. Methods 2006, 154:30-37.
30. Seredenin S.B., Romanova G.A., Shakova F.M. Neuroprotective effect of afobazole on rats with bilateral local photothrombosis of vessels in the prefrontal cortex. Bull. Exp. Biol. Med. 2008, 145:207-209.
31. Takahashi H., Kirsch J.R., Hashimoto K., London E.D., Koehler R.C., Traystman R.J. PPBP [4-phenyl-1-(4-phenylbutyl) piperidine] decreases brain injury after transient focal ischemia in rats. Stroke 1996, 27:2120-2123.
32. Wemmie J.A., Coryell M.W., Askwith C.C., Lamani E., Leonard A.S., Sigmund C.D., Welsh M.J. Overexpression of acid-sensing ion channel 1a in transgenic mice increases acquired fear-related behavior. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:3621-3626.
33. WHO World Health Statistics 2011 2011, 170. World Health Organization, Geneva, Switzerland.
34. Xiong Z.G., Zhu X.M., Chu X.P., Minami M., Hey J., Wei W.L., MacDonald J.F., Wemmie J.A., Price M.P., Welsh M.J., Simon R.P. Neuroprotection in ischemia: blocking calcium-permeable acid-sensing ion channels. Cell 2004, 118:687-698.
35. Zenina T.A., Gavrish I.V., Melkumyan D.S., Seredenina T.S., Seredenin S.B. Neuroprotective properties of afobazol in vitro. Bull. Exp. Biol. Med. 2005, 140:194-196.